Stock 3001 KATAKURA INDUSTRIES CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Katakura Industries Co.,Ltd.

Equities

3001

JP3211400001

Pharmaceuticals

Delayed Japan Exchange
Other stock markets
 02:00:00 2024-05-01 am EDT 		5-day change 1st Jan Change
1,868 JPY -3.21% Intraday chart for Katakura Industries Co.,Ltd. +1.58% +14.04%
2023 Tranche Update on Katakura Industries Co.,Ltd.'s Equity Buyback Plan announced on November 9, 2023. CI
2023 Katakura Industries Co.,Ltd.'s Equity Buyback announced on November 9, 2023, has closed with 143,500 shares, representing 0.43% for ¥239.89 million CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 39,017 47,854 45,709 81,885 57,557 54,183
Enterprise Value (EV) 1 28,073 34,798 26,900 58,384 41,002 35,545
P/E ratio 30.4 x 27.6 x 16.1 x 16.7 x 20.5 x 17.8 x
Yield 1.08% 0.88% 1.2% 0.65% 0.92% -
Capitalization / Revenue 0.88 x 1.09 x 1.15 x 2.18 x 1.68 x 1.36 x
EV / Revenue 0.63 x 0.79 x 0.68 x 1.55 x 1.2 x 0.89 x
EV / EBITDA 5.86 x 6.14 x 4.11 x 9.64 x 10.1 x 5.5 x
EV / FCF 8.71 x 12.9 x 3.84 x 20.1 x -22.8 x 21.9 x
FCF Yield 11.5% 7.77% 26.1% 4.97% -4.39% 4.57%
Price to Book 0.71 x 0.8 x 0.79 x 1.31 x 0.82 x 0.73 x
Nbr of stocks (in thousands) 35,056 35,058 34,367 33,219 33,155 33,079
Reference price 2 1,113 1,365 1,330 2,465 1,736 1,638
Announcement Date 3/28/19 3/27/20 3/30/21 3/30/22 3/30/23 3/28/24
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 44,308 44,043 39,639 37,627 34,274 39,972
EBITDA 1 4,788 5,667 6,552 6,056 4,049 6,463
EBIT 1 1,532 2,569 3,597 2,798 1,371 3,804
Operating Margin 3.46% 5.83% 9.07% 7.44% 4% 9.52%
Earnings before Tax (EBT) 1 2,091 3,066 4,468 7,489 3,781 4,562
Net income 1 1,283 1,732 2,871 4,953 2,817 3,045
Net margin 2.9% 3.93% 7.24% 13.16% 8.22% 7.62%
EPS 2 36.55 49.40 82.70 147.5 84.88 91.89
Free Cash Flow 1 3,221 2,702 7,010 2,899 -1,799 1,624
FCF margin 7.27% 6.14% 17.68% 7.7% -5.25% 4.06%
FCF Conversion (EBITDA) 67.28% 47.69% 106.99% 47.87% - 25.13%
FCF Conversion (Net income) 251.07% 156.03% 244.16% 58.53% - 53.33%
Dividend per Share 2 12.00 12.00 16.00 16.00 16.00 -
Announcement Date 3/28/19 3/27/20 3/30/21 3/30/22 3/30/23 3/28/24
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2021 S1 2021 Q3 2022 Q1 2022 S1 2022 Q3 2023 Q1 2023 S1 2023 Q3
Net sales 1 19,838 22,697 22,014 6,597 8,545 17,164 7,697 10,700 20,616 9,832
EBITDA - - - - - - - - - -
EBIT 1 - 2,651 3,060 -255 -903 14 541 1,051 2,104 1,071
Operating Margin - 11.68% 13.9% -3.87% -10.57% 0.08% 7.03% 9.82% 10.21% 10.89%
Earnings before Tax (EBT) 1 - 1,794 7,298 -42 -676 1,737 725 1,259 2,829 1,178
Net income 1 - 1,008 5,073 101 266 1,631 382 990 1,982 728
Net margin - 4.44% 23.04% 1.53% 3.11% 9.5% 4.96% 9.25% 9.61% 7.4%
EPS 2 9.690 28.84 149.9 3.790 8.030 49.13 11.54 29.86 59.79 21.96
Dividend per Share - - - - - - - - - -
Announcement Date 2/14/20 8/13/20 8/12/21 11/8/21 5/12/22 8/9/22 11/10/22 5/11/23 8/9/23 11/9/23
1JPY in Million2JPY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 10,944 13,056 18,809 23,501 16,555 18,638
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 3,221 2,702 7,010 2,899 -1,799 1,624
ROE (net income / shareholders' equity) 1.89% 2.44% 4.03% 6.07% 2.96% 3.72%
ROA (Net income/ Total Assets) 0.68% 1.15% 1.63% 1.27% 0.62% 1.71%
Assets 1 189,933 150,976 175,844 388,562 457,157 177,852
Book Value Per Share 2 1,560 1,710 1,686 1,884 2,108 2,258
Cash Flow per Share 2 822.0 794.0 924.0 1,039 919.0 899.0
Capex 1 1,527 2,727 1,114 925 817 1,041
Capex / Sales 3.45% 6.19% 2.81% 2.46% 2.38% 2.6%
Announcement Date 3/28/19 3/27/20 3/30/21 3/30/22 3/30/23 3/28/24
1JPY in Million2JPY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
KATAKURA INDUSTRIES CO.,LTD. Stock Katakura Industries Co.,Ltd.
+14.04% 405M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+34.00% 704B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+29.29% 577B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.75% 348B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.53% 327B
ABBVIE INC. Stock AbbVie Inc.
+4.95% 288B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.79% 234B
NOVARTIS AG Stock Novartis AG
+4.93% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-9.78% 194B
AMGEN INC. Stock Amgen Inc.
-4.89% 147B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 3001 Stock
  4. Financials Katakura Industries Co.,Ltd.